Indivior PLC
Indivior PLC (IZQVF) Stock Overview
Explore Indivior PLC’s financial performance, market position, analyst ratings, and future outlook.
IZQVF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Indivior PLC (IZQVF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $73.46.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 604.97 and a market capitalization of 2.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Mark Crossley
1,000
10710 Midlothian Turnpike, North Chesterfield, VA
2014